Nucana Plc (NCNA) Return on Investment ROI from the fourth quarter of 2025 to fourth quarter of 2024 and for the year 2025, average high and low, overall ranking from Dec 31 2025 to Dec 31 2024 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Nucana Plc  (NASDAQ: NCNA)


Nucana Plc's ROI from its fourth quarter of 2025 to the fourth quarter of 2024 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Nucana Plc's ROI in the fourth quarter of 2025?
Nucana Plc recorded a cumulative net loss of $-71 million during 12 months ending in the fourth quarter of 2025, resulting in a negative return on investment (ROI) of -210.62%.

Within the Healthcare sector 758 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the third quarter of 2025 from 0 to 4726.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Dec 31 2025)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Dec 31 2024)
IV. Quarter
Y / Y Investment Change TTM 340.85 % 157.64 % 53.53 % -7.69 % -58.11 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 34 34 34 34 8
Return On Investment (TTM) -210.62 % -207.98 % -273.51 % -234.07 % -433.45 %
NCNA's Overall Ranking # 4726 # 0 # # #
Seq. Investment Change TTM 23.99 % 31.51 % 46 % 85.18 % -27.54 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -71 -56 -56 -33 -33

NCNA Company Profile >> Back to NCNA Roi Comparisons >> See Annual NCNA Return On Investment



Return On Investment NCNA's Ranking
Within: No.
Industry # 351
Sector # 759
Overall # 4726

Return On Investment Statistics
High Average Low
-17.75 %
-69.62 %
-150.23 %
(Sep 30 2018)   (Dec 31 2024)



  News about Nucana Plc Return on Investment ROI

Balancing Hope and Financial Reality The Case of NUC-7738 in Melanoma Treatment

September 14, 2024

As the fight against melanoma continues, innovative therapeutic combinations are critical for managing patients who are refractory or resistant to existing treatments. Nucana Plc s recent presentation at the ESMO Congress 2024 highlights promising results for NUC-7738 in combination with pembrolizumab. However, the company faces financial challenges that cast a shadow on the optimistic clinical outcomes. This article will explore both the scientific advancements and the economic context of Nucana s current situation. Melanoma, a particularly aggressive form of skin cancer, presents treatment challenges, especially for patients who have become refractory or resistant to current immunotherapies such as PD-1 inhibitors. The recent ESMO Congress 2024 saw Nucana Plc unveil its findings regarding NUC-7738, a promising new therapeutic agent that, when combined with pembrolizumab, showed encouraging results in extending progression-free survival (PFS) and demonstrating a favorable safety profile.

NuCanas Turning Point Discontinuation of NuTide323 Amidst Strategic Reassessments in Colorectal Cancer Treatments

August 29, 2024

NuCana Plc has recently taken a critical step in its clinical development strategy by announcing the discontinuation of its Phase 2 randomized colorectal cancer study, referred to as NuTide:323. This decision follows a pre-planned initial analysis and recommendation from the study s steering committee, highlighting a potential pivot in the company’s focus and resources. Key Developments 1. Discontinuation of NuTide:323 : The NuTide:323 study aimed to assess the effectiveness of NuCana s candidate, Acelarin, as a treatment for colorectal cancer. However, the interim analysis indicated that the primary endpoint was unlikely to be met, prompting the steering committee to recommend halting the study. This marks a significant moment for NuCana, a company entrenched in the fight against some of the most challenging cancers.2. Revenue Implications : As the company moves forward with a diminished pipeline for colorectal cancer treatments, the impact on revenue streams is a pressing concern. To date, NuCana has faced delays and setbacks in realizing income from corporate clients, reflected in its reports asserting revenue stagnation. The discontinuation of NuTide:323 may exacerbate these challenges, as investor confidence might wane following the halt in this promising trial.





Financial Statements
Nucana Plc's IV. Quarter Investments $ 34 Millions NCNA's Balance sheet
Nucana Plc's IV. Quarter Income $ -39 Millions Quarterly NCNA's Income Statement
NCNA's Income by Division See NCNA's Income by Division


NCNA Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 33 8 19 47 89
Y / Y Investment Growth 339.3 % -60.41 % -59.06 % -47.12 % -34.79 %
Net Income in Millions -39 -24 -34 -40 -56
Y / Y Net Income Growth - - - - -
Annual Return On Investment -115.84 % -319.11 % -178.86 % -84.39 % -62.84 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
NCNA's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for NCNA's Competitors
Subscribers only: Roi for Nucana Plc's Suppliers
Subscribers only: Return On Investment for NCNA's Customers

Other Ratios
NCNA's Roa NCNA's Inventory Turnover Ratio NCNA's Growth Rates NCNA's Dividend Statistics
NCNA's Profitability Ratios NCNA's Asset Turnover Ratio NCNA's Dividend Growth
NCNA's Roe NCNA's Valuation Ratios NCNA's Financial Strength Ratios NCNA's Dividend Payout Ratio



Companies with similar Return On Investment at Dec 31 2025, within Healthcare Sector ROI

Date modified: 2026-09-09T12:37:50+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.